Literature DB >> 2537608

Effect of dithranol treatment on arachidonic acid and its lipoxygenase products in psoriasis.

R M Barr1, E Wong, F M Cunningham, A I Mallet, M W Greaves.   

Abstract

The concentrations of arachidonic acid and its lipoxygenase metabolites were measured in exudates from lesional psoriatic skin during treatment with 0.25% dithranol (anthralin) applied topically for 10 days. Dithranol caused a reduction in the concentration of arachidonic acid at 10 days (167 +/- 42 and 358 +/- 55 ng ml-1 treated and control sites respectively, p less than 0.05) concurrent with clinical improvement of the lesions. Neither 12-hydroxyeicosatetraenoic acid nor leukotriene B4 concentrations were significantly affected. These results do not support the view that lipoxygenase products are of major importance in the pathogenesis of psoriasis.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2537608     DOI： 10.1007/bf00427659

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN： 0340-3696            Impact factor:   3.017


  13 in total

1.  The responses of normal and psoriatic skin to single and multiple topical applications of leukotriene B4.

Authors:  E Wong; R D Camp; M W Greaves
Journal:  J Invest Dermatol       Date:  1985-05       Impact factor: 8.551

2.  Topical steroid treatment reduces arachidonic acid and leukotriene B4 in lesional skin of psoriasis.

Authors:  E Wong; R M Barr; F M Cunningham; K Mistry; P M Woollard; A I Mallet; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

3.  Anthralin (1,8-dihydroxyanthrone) is a potent inhibitor of leukotriene production and LTB4-omega oxidation by human neutrophils.

Authors:  J M Schröder
Journal:  J Invest Dermatol       Date:  1986-11       Impact factor: 8.551

4.  The analysis of arachidonic acid metabolites in normal, uninvolved and lesional psoriatic skin.

Authors:  R M Barr; E Wong; A I Mallet; L A Olins; M W Greaves
Journal:  Prostaglandins       Date:  1984-07

5.  The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis.

Authors:  S Brain; R Camp; P Dowd; A K Black; M Greaves
Journal:  J Invest Dermatol       Date:  1984-07       Impact factor: 8.551

6.  Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis.

Authors:  S Hammarström; M Hamberg; B Samuelsson; E A Duell; M Stawiski; J J Voorhees
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

7.  Leukotriene B4 and 12-hydroxyeicosatetraenoic acid stimulate epidermal proliferation in vivo in the guinea pig.

Authors:  C C Chan; L Duhamel; A Ford-Hutchison
Journal:  J Invest Dermatol       Date:  1985-10       Impact factor: 8.551

8.  Leukotrienes B4, C4 and D4 stimulate DNA synthesis in cultured human epidermal keratinocytes.

Authors:  K Kragballe; L Desjarlais; J J Voorhees
Journal:  Br J Dermatol       Date:  1985-07       Impact factor: 9.302

Review 9.  Anthralin: historical and current perspectives.

Authors:  R E Ashton; P Andre; N J Lowe; M Whitefield
Journal:  J Am Acad Dermatol       Date:  1983-08       Impact factor: 11.527

10.  Increased aggregation and arachidonic acid transformation by psoriatic platelets: evidence that platelet-derived 12-hydroxy-eicosatetraenoic acid increases keratinocyte DNA synthesis in vitro.

Authors:  K Kragballe; J D Fallon
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.